197 results about "Hepatitis" patented technology

The invention belongs to the technical field of biology, and particularly relates to a mouse hepatitis virus antibody or an antigen binding fragment thereof as well as a preparation method and application thereof. The antibody or the antigen binding fragment thereof can specifically recognize and bind to the mouse hepatitis virus or the NSP3 protein thereof, and has good affinity with the mouse hepatitis virus or the NSP3 protein thereof; the kit can be used for preparing products for diagnosing, preventing and / or treating mouse hepatitis virus infection or diseases caused by the mouse hepatitis virus infection, detecting existence or level of mouse hepatitis virus or NSP3 protein in a sample, screening medicines for preventing and / or treating the mouse hepatitis virus infection or the diseases caused by the mouse hepatitis virus infection, and carrying out basic research and / or vaccine development.

The invention relates to the technical field of hepatitis diagnosis and treatment management, and discloses a block chain-based hepatitis patient full-period management method. The method comprises the following steps: creating a patient identity chain in a block chain network, and storing patient registration data and initial diagnosis information; full-cycle diagnosis and treatment data of a patient are obtained and divided into clinical examination, iconography, medication records and life sign monitoring data. Performing multi-dimensional cleaning on the clinical examination data to generate a standardized data set; inputting the iconography data into a pre-trained hepatitis feature extraction model, and outputting a liver injury feature set; verifying the integrity of the medication record, and generating a non-tampering medication time sequence chain; comparing the life sign monitoring data with preset health reference parameters to generate a sign deviation coefficient set; according to the method, data safety and traceability are guaranteed through the block chain, diagnosis and treatment data quality is improved through multi-dimensional data processing, patient privacy is protected, and reliable support is provided for full-period management of hepatitis patients.

The invention discloses a CRISPR / Cas12a-RPA (clustered regularly interspaced short palindromic repeats / CRISPR associated protein 12a-recombinase polymerase amplification)-based sequence combination for rapidly detecting mouse hepatitis virus and a kit thereof, and belongs to the technical field of biological detection The sequence combination comprises an RPA primer pair sequence, a crRNA sequence and an ssDNA probe sequence; the kit comprises an RPA primer pair sequence, a crRNA sequence and an ssDNA probe sequence, the kit further comprises a mouse hepatitis virus negative control standard substance, RNase-free water, an RPA reaction buffer solution, an NEB buffer solution, Lba Cas12a nuclease, dry powder RPA reaction microspheres containing recombinase polymerase and magnesium acetate with the concentration of 280 mM. The kit can be used for rapidly detecting the mouse hepatitis virus. The primer sequence combination provided by the invention is good in conservative property and specificity and relatively high in sensitivity, and rapid detection of the mouse hepatitis virus can be realized.

The invention provides an application of a compound Aldometanib in preparation of a medicine for preventing and treating immune-related adverse reactions and diseases. Based on the first discovered prevention and treatment effects of Aldometanib on fatal immune hepatitis, immune myocarditis, pneumonia and enteritis, the invention specifically discloses application of Aldometanib in preparation of drugs for prevention and treatment of immune-related adverse reactions and diseases, and the main mechanism is that Aldometanib activates immune cells AMPK, enhances catabolism of immune cells, promotes immune cell apoptosis, promotes immune cell apoptosis, and improves immune cell apoptosis. The anabolism of the immune cells is inhibited, so that the expression of effector factors of the immune cells is controlled, and inflammatory factor storm is inhibited. Aldometanib has the effects of preventing the occurrence of immune-related adverse reactions and diseases, and inhibiting the attack levels of the immune-related adverse reactions and diseases, so that non-lethal and lethal injuries caused by an immune system to body organs are reduced.

The invention discloses a quantitative index determination method and device based on a hepatitis pathology image, equipment, a medium and a product, and relates to the field of medical pathology image artificial intelligence analysis, and the method comprises the steps: obtaining an image of a liver puncture pathology section; according to the image of the hepatic puncture pathological section, performing feature extraction by using a multi-stage model cascade architecture to obtain a pathological feature result; the multi-stage model cascade architecture comprises an improved VM-UNet segmentation model and a VM classification model based on FEM enhancement, and the VM classification model is connected with the improved VM-UNet segmentation model; the pathological feature result comprises the expansion level of the manifold area, the necrosis type of the manifold area and the inflammatory cell information of the manifold area; and calculating a quantitative index according to the pathological feature result. According to the invention, the accuracy, objectivity, consistency and repeatability of identification can be improved.

Disclosed herein are nucleic acid compositions and methods of use. The nucleic acid compositions may have a therapeutic nucleic acid sequence operably linked to a nuclear targeting sequence that increases expression of the therapeutic nucleic acid in a cell by at least 1.25 fold; at least 80% sequence identity to SEQ ID NO: 6; or a first regulatory element comprising a promoter sequence operably linked to a hemoglobin subunit gamma intron (hBGi) sequence, and a second regulatory element comprising a woodchuck hepatitis posttranscriptional regulatory element (WPRE) sequence. The nucleic acid compositions with these features may enhance therapeutic nucleic acid transfection and expression. Also disclosed herein are transgenes optimized for gene therapy applications, including novel FVIII transgene sequences, in which the B domain may be non-naturally occurring the A1 and / or A3 domain may include at least one amino acid substitution.

The invention discloses an application of TFPI2 in preparation of an anti-hepatitis B virus drug. Through in-depth study, it is found for the first time that overexpressed TFPI2 can significantly inhibit the replication ability of HBV on the cellular level and the animal level, and the expression level of HBV DNA and HBV RNA and the secretion level of HBsAg and HBeAg are reduced. Besides, mechanism analysis finds that overexpression TFPI2 promotes degradation of hepatitis B virus X protein (HBx), the half-life period of the HBx protein is remarkably shortened, and finally the HBV replication ability is damaged. Based on the research results, the application of the TFPI2 in chronic viral hepatitis B is provided for the first time, and candidate treatment targets and backup protein drugs are provided for clinical treatment of chronic hepatitis B patients.

The invention provides a polypeptide for activating cellular immunity in chronic hepatitis B and application of the polypeptide, and belongs to the technical field of biological medicine. A polypeptide library is designed and synthesized on the basis of a preS1 structural domain for coding HBV large HBsAg, a full-length core protein Core, a polymerase protein fragment rich in T cell epitopes and an mRNA-PreS1CPX holoantigen sequence (as shown in SEQ ID NO.1) of full-length X protein HBX, and peptide fragments capable of activating T cell immunity are screened by utilizing ELISPOT and flow cytometry. Experimental results show that the polypeptide sequences as shown in SEQ ID NO.2-15 can promote HBV antigen specific immune response by stimulating CD8 + T lymphocytes to secrete IFN-gamma, so that immune activation treatment of hepatitis B is realized.

The present application relates to derivatives of STOPS™ antiviral compounds having enhanced helicity, wherein the compounds are S-antigen transport inhibiting oligonucleotide polymers. This application further relates to processes for making the compounds and methods of using them to treat diseases and conditions. In some embodiments, the diseases and conditions are related to hepatitis B and / or hepatitis D.

The invention provides a nano-phase penthorum chinense pursh extract, which is prepared by the following steps: soaking a penthorum chinense pursh medicinal material, decocting, filtering, collecting filtrate, carrying out layering centrifugation to remove precipitate, dialyzing supernate by adopting a dialysis bag with the molecular weight cutoff of 3.5 kDa, and freeze-drying dialysate to obtain the nano-phase penthorum chinense pursh extract. The invention further provides a preparation method and application of the nanometer phase-state penthorum chinense pursh extract. The invention provides an extraction method capable of accurately separating 50-200nm phase-state active components in a nanometer phase-state penthorum chinense pursh extract traditional Chinese medicine. Organic solvents are prevented from being used, and the safety of extracted products is improved; the purity of the target component is improved; the structural integrity of a natural nanometer phase state is kept; the obtained nanometer phase-state extract has the effects of remarkably improving metabolic dysfunction related steatohepatitis and resisting coagulation, is high in separation efficiency, can be completed in 2-3 days, and can be applied on a large scale; the equipment is simple and low in cost.

The application discloses a tripterine self-assembled nanoparticle microsphere, a preparation method and application thereof, and belongs to the technical field of biological medicines. The tripterine self-assembled nanoparticle microsphere takes tripterine self-assembled nanoparticles as a drug core, is formed by cross-linking of a sodium alginate-pectin composite carrier through calcium ions, can significantly improve drug solubility, realizes stable protection and intestinal targeting rapid release in the gastrointestinal tract, and effectively reduces drug systemic exposure and side effect risks. The preparation process is mild and simple, the obtained preparation has high targeting and safety. Pharmacodynamic results show that the microsphere can obviously improve liver steatosis, inflammation and fibrosis related to metabolic-related fatty liver hepatitis, and has better curative effect than conventional preparations. The application provides a novel oral delivery system for preventing and treating metabolic-related fatty liver hepatitis, and has good industrial and clinical transformation prospects.

The invention discloses a method for predicting the survival state of duck against hepatitis A virus infection. The method comprises the following steps: (1) constructing a PCA (Principal Component Analysis) prediction model by taking the contents of IFN-alpha and IFN-beta of duck blood as variables; (2) measuring the contents of IFN-alpha and IFN-beta in the duck blood to be measured; and (3) substituting the measured contents of IFN-alpha and IFN-beta in the duck blood into the prediction model, and predicting the anti-hepatitis A virus infection survival state of the duck to be detected according to the family background of the individual in combination with the output result of the prediction model. According to the method, ROC curves and corresponding AUC values of different prediction models in the aspect of predicting the survival state are compared, and the result shows that the AUC value of the PCA prediction model is the highest, and the sensitivity and the specificity are most prominent. Based on the prediction model provided by the invention, the Beijing duck individuals or strains with strong disease resistance can be rapidly screened, and the prediction model has an application prospect in duck disease resistance breeding or duck virus hepatitis prevention.

The present invention provides gene therapies for the treatment of Friedreich's ataxia. Specifically, the present invention provides a nucleic acid, cloning vector and transfer vector for the production of an adeno-associated virus (AAV) vector. The nucleic acid comprises (i) a nucleic acid sequence encoding frataxin, (ii) a phospho-glycerate-kinase (PGK) promoter, and (iii) a woodchuck hepatitis virus posttranscriptional regulatory element (WPRE). The present invention also provides a pharmaceutical composition which comprises the AAV vector or nucleic acid. Also, the AAV vector, nucleic acid or pharmaceutical composition can be used as a medicament, specifically as a medicament for the treatment of Friedreich's ataxia.

The present invention belongs to the field of biomedical technology and provides an application of betulinone and its analogs in the prevention and treatment of fatty liver disease and adjuvant lipid-lowering. The present invention also provides a composition for treating fatty liver disease or adjuvant lipid-lowering, which comprises an effective dose of betulinone and its analogs. The betulinone and its analogs provided by the present invention have the effects of reducing blood triglyceride and liver triglyceride in vivo, reversing liver steatosis, and can improve liver fibrosis and inflammatory symptoms of mice with fatty hepatitis, and have good safety and no toxic side effects, and can be used for preparing preventive and therapeutic drugs for fatty liver disease, fatty hepatitis and related diseases.

Described are methods for treating alpha-1 antitrypsin deficiency (AATD) in a human patient in need of treatment, using pharmaceutical compositions that include AAT RNAi agents. The pharmaceutical compositions disclosed herein that include AAT RNAi agents, when administered to a human patient in need thereof, treat liver diseases associated with AAT deficiency such as chronic hepatitis, cirrhosis, increased risk of hepatocellular carcinoma, transaminitis, cholestasis, fibrosis, fulminant hepatic failure, and other liver-related diseases.

This invention discloses an anti-hepatitis active composition, its preparation method, and its application. The anti-hepatitis active composition, by mass percentage, comprises 70.3±0.4% cucurbitacin B, 26.1±0.2% isocucurbitacin B, and 3.6±0.3% cucurbitacin E. Using widely available sunflower seed shells as raw material, this invention obtains a high-purity, quality-controllable anti-hepatitis active composition by optimizing the extraction solvent, eluent composition, and chromatographic detection methods, ensuring the uniformity and controllability of TCs quality. Compared with cucurbitacin tablets, the anti-hepatitis active composition of this invention has a higher median lethal dose (LD50) and a NOAEL of 15 mg / kg BW, exhibiting higher safety.

The invention relates to the technical field of traditional Chinese medicine, in particular to a traditional Chinese medicine composition for treating hepatobiliary diseases, the traditional Chinese medicine composition has the effects of soothing liver-gallbladder, clearing away heat and toxic materials, promoting qi circulation, dispersing blood stasis, regulating qi, activating blood, benefiting gallbladder and removing urinary calculus, and is clinically used for treating cholelithiasis, cholecystitis, jaundice, hepatitis and other diseases. The preparation has the advantages of good curative effect, small side effect, low price, convenience in taking and the like, and exerts the unique advantage of the traditional Chinese medicine in treating hepatobiliary diseases.

To provide novel agents for the treatment or prevention of Epstein-Barr virus hepatitis. [Solution] A pharmaceutical composition for the treatment or prevention of Epstein-Barr virus hepatitis in a subject, comprising ibudilast, dipyridamole, or both as active ingredients.

The invention relates to new proline derivatives of formula (I) as cGAS inhibitors,whereinwherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and G are defined as in claim 1, and prodrugs or pharmaceutically acceptable salts of these compoundsfor the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), non alcoholic steatotic hepatitis (NASH), interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF).

The application belongs to the technical field of biological detection, and particularly relates to the use of apolipoprotein A-I in the preparation of a diagnostic reagent or system for predicting the risk of severe acute hepatitis E. The application first discloses and verifies the significant correlation between the serum apolipoprotein A-I (apoA-I) level and the adverse clinical outcomes (including severe jaundice, liver failure and death) of patients with acute hepatitis E, and establishes the risk interpretation threshold (0.675 g / L and 0.435 g / L) with clinical practical value. The application can objectively and early identify high-risk patients, and provides a powerful auxiliary tool for clinical stratified management and resource optimization.

The present disclosure relates to SH3YL1 monoclonal antibodies and compositions comprising the SH3YL1 monoclonal antibodies. The disclosure also relates to isolated nucleic acid molecules encoding the SH3YL1 antibodies, vectors comprising the nucleic acid molecules, and host cells comprising the vectors. Also disclosed are methods of modulating an immune response, methods of treating diabetic nephropathy, and methods of treating non-alcoholic steatosis hepatitis comprising administering the SH3YL1 antibodies. Also disclosed are methods of treating acute kidney injury and methods of treating inflammatory bowel disease comprising administering the SH3YL1 antibodies.

The present invention discloses an application of a reagent for detecting the methylation level of molecular markers in the preparation of a reagent product for detecting primary hepatocellular carcinoma, belonging to the technical field of gene detection. This solution can identify whether the patient from whom the sample is derived is a patient with primary hepatocellular carcinoma by detecting the methylation level of CpG sites in the region of chr17: 30970241-30970741. If the target sample is from a patient with primary hepatocellular carcinoma, the CpG sites in the above region are at a high methylation level; if the target sample is from a healthy person or a patient with a benign liver disease (such as cirrhosis, hepatitis, etc.), the CpG sites in the above region are at a low methylation level. The CpG sites in this region can be used to distinguish between samples from patients with primary hepatocellular carcinoma and samples from healthy people, as well as between samples from patients with primary hepatocellular carcinoma and samples from patients with benign diseases (such as cirrhosis, hepatitis, etc.).

The application provides a liver-protecting medicinal and edible Chinese medicine composition, a medicinal and edible Chinese medicine preparation and a preparation method and application, and specifically belongs to the technical field of medicinal and edible Chinese medicines. The medicinal and edible Chinese medicine composition comprises the following components in parts by weight: Cassia seed 1-3.5 parts, jujube seed 0.5-2.5 parts, Phyllanthus emblica 0.1-1.5 parts and Prunella vulgaris 0.1-1.5 parts. The medicinal and edible Chinese medicine composition has the effects of significantly improving fatty liver and non-alcoholic fatty hepatitis, and can provide a low-cost and non-toxic side-effect strategy for preventing or treating non-alcoholic fatty hepatitis.

The present invention relates to the compound 2-hydroxy-octadecene-9-cis-oate for use in the treatment of oncological pathologies including grade IV glioblastoma with native IDH, grade 3 glioma, embryonal tumour, pituitary tumour, meningioma, haemangiopericytoma, haemangioblastoma, mesothelioma, bile duct adenocarcinoma, exocrine pancreatic cancer, neuroendocrine pancreatic cancer, rectal cancer, urachal cancer, adenocarcinoma of the bladder and oesophageal cancer, and for the treatment of neuropathic pain caused by diabetic peripheral neuropathy, spinal cord injury, post-herpetic neuralgia, chemotherapeutic agent, antitumour agent, cancer, fibromyalgia or hepatitis. The present invention also relates to the pharmaceutical composition comprising 2-hydroxy-octadecene-9-cis-oate.

Methods of treating hepatitis delta virus (HDV) infection in a human subject are provided. In some embodiments, the methods comprise administering to the subject a therapeutically effective amount of lonafarneb and ritonavir, with or without pegylated interferon alpha.

The invention relates to new proline derivatives of formula (I) as cGAS inhibitors,whereinwherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and G are defined as in claim 1, and prodrugs or pharmaceutically acceptable salts of these compoundsfor the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), non-alcoholic steatotic hepatitis (NASH), interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF).

The present application provides combinations of bulevirtide, or a pharmaceutically acceptable salt thereof, and ribavirin, or a pharmaceutically acceptable salt thereof, useful for treating hepatitis D virus (HDV) infection.

The disclosure features Rep / Helper plasmids comprising a cytomegalovirus (CMV) promoter, an E2A gene, an E4 gene, a VA gene and a rep gene, or a cytomegalovirus (CMV) promoter, an E2A gene, a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE), an E4 gene, a VA gene and a rep gene, or an E2A gene, an E4 gene, a VA gene, a Kozak consensus sequence and a rep gene, where the plasmid does not comprise a nucleic acid sequence encoding a cap gene.

The present invention provides a drug for treating and / or preventing enteritis and / or hepatitis, said drug containing D-amino acid as an active ingredient. In addition, the present invention provides a food composition for suppressing enteritis and / or hepatitis, said composition containing D-amino acid as an active ingredient. In addition, the present invention provides a method for assisting diagnosis of enteritis and / or hepatitis in a subject, said method using the amount of D-amino acid in the intestinal tract as an indicator.